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Abstract
Background: Osteopontin is a secreted phosphoglycoprotein that is expressed by a number of normal cells as well
as a variety of tumor cells. With respect to breast cancer, osteopontin has been implicated in regulating tumor cell
proliferation and migration/metastasis and may serve as a prognostic indicator. However it remains unclear whether
osteopontin has the same impact in all breast cancer subtypes and in particular, osteopontin’s effects in
claudin-low breast cancer are poorly understood.
Methods: cDNA microarrays and qRT-PCR were used to evaluate osteopontin expression in mammary tumors from
MTB-IGFIR transgenic mice and cell lines derived from these tumors. siRNA was then used to determine the impact
of osteopontin knockdown on proliferation, apoptosis and migration in vitro in two murine claudin-low cell lines as
well as identify the receptor mediating osteopontin’s physiologic effects.
Results: Osteopontin was expressed at high levels in mammary tumors derived from MTB-IGFIR transgenic mice
compared to normal mammary tissue. Evaluation of cell lines derived from different mammary tumors revealed that
mammary tumor cells with claudin-low characteristic expressed high levels of osteopontin whereas mammary
tumor cells with mixed luminal and basal-like features expressed lower levels of osteopontin. Reduction of
osteopontin levels using siRNA significantly reduced proliferation and migration while increasing apoptosis in the
claudin-low cell lines. Osteopontin’s effect appear to be mediated through a receptor containing ITGAV and not
through CD44.
Conclusions: Our data suggests that mammary tumors with a mixed luminal/basal-like phenotype express high
levels of osteopontin however this osteopontin appears to be largely produced by non-tumor cells in the tumor
microenvironment. In contrast tumor cells with claudin-low characteristics express high levels of osteopontin and a
reduction of osteopontin in these cells impaired proliferation, survival and migration.
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Background
Osteopontin (OPN, Spp1) is a secreted glycophospho-
protein expressed by a number of cell types including
endothelial cells, vascular smooth muscle cells, neural
cells, epithelial cells, osteoblasts/osteoclasts, and im-
mune cells [1–3]. OPN is involved in normal processes
including wound healing, bone remodelling and inflam-
mation as well as pathological processes such as cancer
[4–7]. OPN mediates its actions through binding to
integrins including αvβ1, αvβ3, αvβ5, αvβ6, α4β1, α5β1,
α8β1, and α9β1 as well as CD44 [8–10].
In the mid-1990’s OPN mRNA and protein were found
to be elevated in a number of different tumors compared
to matching control tissue [11, 12]. Elevated levels of
OPN have been found in tumors of the breast, prostate,
colon, ovary, stomach, lung and liver [13–22]. OPN has
been observed both in tumor cells themselves and in
stromal cells surrounding the tumor [23]. More recent
studies have shown that OPN is also elevated in the
serum of breast cancer patients including those with
early stage disease [24]. In breast cancer, OPN has been
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associated with poor prognosis [6, 7] and OPN has been
shown to increase breast cancer cell survival and migra-
tion [25–27]. OPN is found in ER positive breast cancer
and triple negative tumors [28].
Murine mammary tumor models have also been used
to examine OPN’s role in breast tumorigenesis. A study
investigating serum biomarkers in transgenic mice over-
expressing an activated version of c-neu identified 3 pro-
teins significantly elevated in tumor bearing mice
compared to control mice and one of these proteins was
OPN [29]. Interestingly, OPN was also able to discrimin-
ate tumor bearing mice from control mice when mam-
mary tumor development was driven by a mutant p53
protein [29]. The tumors induced by the mutant p53
protein were estrogen receptor positive while the tumors
induced by c-neu expression were estrogen receptor
negative suggesting that OPN is elevated in mammary
tumors with diverse characteristics [29].
In our mouse mammary tumor model, MTB-IGFIR
transgenic mice develop mammary tumors due to ele-
vated expression of the type I insulin-like growth factor
receptor (IGF-IR) in mammary epithelial cells [30]. The
mammary tumors that arise in this model have charac-
teristics of human luminal breast cancer including ex-
pression of cytokeratin 8, cytokeratin 18 and E-cadherin
however, these tumors cluster most closely with human
basal-like breast cancer when gene expression profiles
are used [31, 32]. Expression of the IGF-IR transgene in
the MTB-IGFIR mice is controlled by a doxycycline in-
ducible promoter and thus the impact of the loss of
transgene expression in established mammary tumors
can be evaluated. Loss of IGF-IR transgene expression in
mammary tumors promotes regression followed by
tumor re-growth in a subset of the mice. Mammary
tumor recurrence in the absence of IGF-IR transgene ex-
pression is associated with epithelial to mesenchymal
transition (EMT) [33] and tumors that cluster most
closely with human claudin-low mammary tumors [31].
A number of cell lines have been generated from these
tumors. RJ345 cells share characteristics with the lu-
minal/basal like tumors while RJ348 and RM11A share
characteristics with the claudin-low tumors [34, 35]
DNA microarray analysis comparing wild type mam-
mary tissue to the mammary tumors revealed that Spp1
was the most differentially expressed genes; Spp1 was el-
evated 77-fold in the mammary tumors compared to
normal mammary glands [31]. Spp1 expression remained
high in mammary tumors that acquired a more mesen-
chymal phenotype compared to normal mammary
glands. Therefore, the purpose of this study was to fur-
ther characterize the function of OPN in mammary
tumorigenesis using murine mammary tumor cell lines




The RM11A, RJ348 and RJ345 murine mammary
tumour cells were grown in Dulbecco's modified eagle
medium (DMEM) (Life Technologies Inc., Burlington,
ON) containing the following supplements: 10 %
tetracycline-free fetal bovine serum (FBS) (Clontech,
Mountain View, CA), 1 mM sodium pyruvate, 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 4 mM glutamine, 2 mM hydrocortisone, 5 μg/
ml estrogen, 5 μg/ml prolactin, 10 μg/ml EGF, 10 μg/ml
insulin, 10 μg/ml doxycycline and 1 % antibiotic-
antimycotic (Life Technologies Inc., Burlington, ON).
Cells were maintained at 37 °C and 5 % carbon dioxide.
RNA extraction
For tissue samples, flash-frozen tissues were homoge-
nized using a handheld homogenizer in lysis/binding
buffer from the mirVana miRNA Isolation kit (Life
Technologies Inc., Burlington, ON, Canada). For cell
lines, cells were washed twice in ice cold PBS and the
lysis/binding buffer from the mirVana miRNA Isolation
kit as added directly to the plate. The cells were scraped
off using a cell scraper and the cell-buffer solution was
then collected into 1.5 ml Eppendorf tubes. RNA from
tissue and cell lines was extracted following the manu-
facturer’s protocol (enrichment for small RNAs was not
performed). RNA was eluted with nuclease-free water
and stored at -80 °C.
Quantitative Real-Time PCR
RNA (500 ng) was reversed transcribed using iScript Re-
verse Transcription SuperMix (Bio-Rad Laboratories,
Mississauga, ON, Canada) following the manufacturer’s
protocol. The cDNA was then amplified using qScript
cDNA SuperMix (Quanta Biosciences, Gaithersburg,
MD) and the PrimePCR program on a CFX96 real-time
PCR machine (Bio-Rad Laboratories, Mississauga, ON,
Canada). All primers were purchased from Bio-Rad La-
boratories (Mississauga, ON, Canada) and CFX Manager
software v3.1 (Bio-Rad Laboratories, Mississauga, ON,
Canada) was used to calculate expression levels and pri-
mer efficiencies. Primer efficiencies were as follows,
Spp1 – 104, Itgav – 101, Itgb3 – 99, Cd44 – 101, Hprt –
105, and Ywhaz – 110. The expression of Spp1, Itgav,
Itgb3 and Cd44 were determined relative to the house-
keeping genes Hprt and Ywhaz which were previously
been shown to be suitable from a panel of 14 potential
housekeeping genes [36].
Immunohistochemisty
Tissue sections from formalin-fixed, paraffin-embedded
mammary tumors were de-waxed with xylene and re-
hydrated in 2 changes each of 100 %, 90 % and 70 %
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ethanol followed by incubation in PBS. Sections were
blocked with 5 % BSA in Tris-buffered saline containing
0.1 % triton-X100 at room temperature for 30 min. The
sections were then incubated with the OPN antibody
(Ab8448, Abcam Inc, Toronto, ON) at a 1:200 dilution
in PBS overnight at 4 °C. An anti-rabbit IgG (B7389,
whole molecule) secondary was used at a 1:200 dilution
in PBS for 1 h at room temperature (Sigma-Aldrich
Canada Co, Oakville, ON). Sections were then stained
with hematoxylin, dehydrated and mounted. Sections
lacking the primary antibody were used as a control.
Western blotting
Western blotting was performed as previously described
[30]. Anti-OPN (AKm2A1; Santa Cruz Technologies,
Santa Cruz, MA) and anti-β-actin (Cell Signaling Tech-
nology Beverly, MA) were used at a 1:1,000 dilution in
5 % skim milk in Tris-buffered Saline (TBS) containing
0.01 % Tween 20 (TBST). An anti-mouse secondary was
used for detection of OPN while an anti-rabbit second-
ary was used for the detection of β-actin. Both secondary
antibodies were obtained from Cell Signaling Technol-
ogy (Beverly, MA) and were used at a 1:2,000 dilution in
5 % skim milk in TBST. Bands were visualized using
Western Lightning Chemiluminescence substrate (Per-
kin Elmer, Wellesley, MA, USA) and a FluorChem 9900
gel documentation imaging system (Alpha Innotech, San
Leandro, CA).
Transient OPN Knockdown (siRNA)
Cells were transfected with stealth RNAi oligonucleo-
tides directed against Spp1, Cd44, Itgav or a guanine-
cytosine (GC) control sequence. All oligonucleotides
were obtained from Life Technologies Inc. (Burlington,
ON, Canada) and were used at a final concentration of
100 nM. Cells were transfected using Lipofectamine
2000 transfection reagent and Opti-MEM media (both
obtained from Life Technologies Inc., Burlington, ON,
Canada). After 4 h, fully supplemented media was added
to the wells and cells were incubated at 37 °C with 5 %
carbon dioxide.
OPN Neutralizing Antibody
The mouse osteopontin neutralizing antibody (cat
#AF808) was purchased from R&D Systems (Minneap-
olis, MN) and used at a concentration of 5 μg/μl or
10 μg/μl. A goat-anti-chicken IgG secondary antibody
(Life Technologies, Burlington, ON, Canada) was used at
5 μg/ml or 10 μg/ml and served as a control.
Immunofluorescence
Cells were plated onto sterile coverslips and were treated
with either siRNA targeting OPN mRNA (described
above) or an OPN neutralizing antibody (described
above) for 48 h. Cells were then washed with PBS and
fixed for 1 h at room temperature in 10 % buffered for-
malin. Coverslips with fixed cells were then washed with
PBS and permeated with 0.1 % Triton X in PBS for
10 min at room temperature. Fixed cells were then
washed once again with PBS, blocked in 5 % BSA for
10 min, and then incubated overnight at 4 °C with the
primary antibody. Primary antibodies were used at a
1:200 dilution and anti-Ki67 (Abcam, Cambridge, MA)
or anti-phospho-histone H3 (Abcam, Cambridge, MA)
were used to identify proliferating cells while anti-
cleaved caspase 3 (Millipore, Etobicoke, ON, Canada)
was used to identify apoptotic cells. Fluorescent second-
ary antibodies were used a 1:100 dilution (Life Technolo-
gies, Burlington, ON, Canada) at room temperature for
2 h. Cells were then counterstained with 4',6-diamidino-
2-phenylindole (DAPI) (Sigma, Oakville, ON, Canada)
and mounted using Prolong Gold mounting media (Invi-
trogen, Burlington, ON, Canada). Images were captured
with an Olympus BX-61 fluorescent microscope and
positively stained cells were counted manually from at
least 4 different, randomly selected fields of the
coverslip.
Cell counting
RJ348 cells were seeded in 6-well plates at a density of
200,000 cells per well. Four hours after seeding (RJ348
cells had attached to the plate at this point), RJ348 cells
were treated with either siRNA targeting OPN mRNA
(described above) or an OPN neutralizing antibody (de-
scribed above) for 48 h. At this point cells were trypsi-
nized, stained with typran blue and counted using a
hemocytometer.
Scratch wound migration assay
Cells where plated in 24-well culture dishes and grown
to ~70-80 % confluency. Cells were then transfected
with siRNA targeting Spp1, Cd44, or Itgav, or a guanine-
cytosine control sequence as described above. Twenty-
four hours post siRNA transfection a scratch was in-
duced using a pipette tip and images were captured im-
mediately after scratch induction as well as 24 h or 48 h
after scratch induction. Images were captured using an
Olympus IX71 inverted microscope (Toronto, ON,
Canada) and Q-capture software (Surrey, BC, Canada).
Image J software [37] was used to quantify the percent
wound closure.
Boyden chamber assay
Matrigel (Life Technologies, Burlington, ON, Canada)
was diluted 1:6 in DMEM (Life Technologies, Burling-
ton, ON, Canada) and 20 μl of diluted matrigel was
plated on to the upper compartment of a Falcon cell cul-
ture insert (cat #353097; BD Bioscience, Mississauga,
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ON, Canada). Approximately 1x105 cells were cultured
in 200 ul of serum-free media in the upper compartment
of the insert. The bottom well was filled with 300 ul of
media containing serum. Cells were cultured at 37 °C
and 5 % carbon dioxide for 20 h. Media was then aspi-
rated from the lower chamber and the bottom of the in-
sert was fixed with 5 % glutaraldehyde in 1xPBS, for
10 min, washed with water and stained with 0.5 % tolui-
dine blue staining solution 10-20 min at room
temperature. The inner surface of the upper chamber
was then wiped clean and cells that had migrated to the
bottom of the insert were visualized using an Olympus
IX71 inverted microscope (Toronto, ON, Canada) and
Q-capture software (Surrey, BC, Canada). The number
of cells on the bottom of the insert were counted
manually.
Statistics
A paired student’s t test was used to compare means
from the treated and control groups. Differences were
considered to be significant at p < 0.05.
Results
OPN expression in mammary tissue, mammary tumors
and mammary tumor cell lines
A previous study from our lab described the DNA
microarray analysis of wild-type mammary tissue (WT),
primary mammary tumors (PMT) and recurrent spindle
tumors (RST) generated in MTB-IGFIR transgenic mice
[31]. PMTs were induced by the transgenic expression of
the type I insulin-like growth factor receptor (IGF-IR) in
mammary epithelial cells of MTB-IGFIR transgenic mice
while RSTs resulted following the downregulation of the
IGF-IR transgene in PMTs. As described in Franks et al.
[31], the most differentially expressed gene between wild
type mammary tissue and primary mammary tumors
was Spp1 or OPN and this was confirmed by qRT-PCR.
Raw and normalized gene expression data is available in
the Gene Expression Omnibus (GEO:GSE32152).
Figure 1 shows the range of Spp1 expression in 8 WT,
12 PMT and 8 RST samples as determined by the DNA
microarray. Each of these tissues/tumors were obtained
from different mice. The WT samples consistently
expressed only very low levels of Spp1 while Spp1 ex-
pression in the tumor samples was more variable. Table 1
shows the average Spp1 expression as determined by the
cDNA microarray. Quantitative RT-PCR was also per-
formed on 4 WT, 4 PMT and 4 RST samples. As shown
in Table 1, although the values were higher for each
group, qRT-PCR confirmed the cDNA microarray data
in that the PMTs had the highest level of Spp1 with the
RSTs having less Spp1 than the PMTs but more than the
WT samples which only expressed very low levels of
Spp1.
OPN was also evaluated in PMTs and RSTs using im-
munohistochemistry. As shown in Fig. 2, OPN protein
in PMTs was primarily expressed by stromal cells sur-
rounding the tumor cells with only low, sporadic stain-
ing of OPN protein being observed in the tumor cells
themselves (Fig. 2a, b). In contrast, high levels of OPN
protein were frequently found in the tumor cells of RSTs
(Fig. 2c, d). Sections lacking the primary antibody did
not display any staining (data not shown).
OPN expression in murine mammary tumor cell lines
To determine whether the tumor cells themselves were
producing OPN, cell lines derived from different MTB-
IGFIR mammary tumors were evaluated. The two best
characterized lines are RJ345 cells (which have charac-
teristics similar to PMT tumors in MTB-IGFIR trans-
genic mice) and RJ348 cells (which have characteristics
similar to RST tumors in MTB-IGFIR transgenic mice)
[34, 38–40]. As shown in Table 2, RJ348 cells expressed
higher levels of Spp1 than RJ345 cells. To confirm that
murine mammary tumor cells with characteristics of hu-
man claudin-low breast cancer [34] express high levels
of Spp1, another cell line, RM11A, which was derived
from a different RST tumor was also examined. As
shown in Table 2, RM11A cells expressed higher levels
of Spp1 than the RJ345 cells. All the tumor cell lines
expressed higher levels of Spp1 than the wild-type mam-
mary tissue but lower levels than the PMTs (Table 1).
Since RM11A cells expressed the highest level of Spp1
we collected conditioned media from these cells and
Fig. 1 Heat map illustrating the expression of OPN in 8 wild type mammary glands (WT), 12 primary mammary tumors (PMT) and 8 recurrent
spindle tumors (RST) that arose in MTB-IGFIR transgenic mice as determined by cDNA microarray analysis. Numerical values in the box represent
OPN expression relative to a universal mouse reference RNA sample. Microarrays were performed using Agilent Whole Mouse Genome 4 × 44 k
Gene Expression Arrays (product number G4122F, Agilent) as described in [31]
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confirmed through western blotting that OPN was de-
tectable in conditioned media of RM11A cells (data not
shown).
Spp1 knockdown decreases proliferation and increases
apoptosis
Since the claudin-low mammary tumor cell lines
expressed higher levels of Spp1 and little is known about
the function of OPN in claudin-low breast cancer, OPN
function was evaluated in the claudin-low cell line
RJ348. OPN was detected as two bands with molecular
weights of ~62 kDa and ~58 kDa and three different
siRNA oligonucleotides targeting different regions of
OPN mRNA suppressed both the 62 kDa and 58 kDa
OPN bands (Fig. 3a). A time course was then performed
using OPN-siRNA2 in RJ348 cells and it was observed
that OPN knockdown was achieved 48 h after RNAi
treatment and OPN protein levels remained low 72 h
after OPN RNAi treatment (Fig. 3b). OPN protein levels
were reduced approximately 60 % following OPN siRNA
treatment. The efficacy of OPN-siRNA2 was confirmed
in RM11A cells (Fig. 3c).
Proliferation was evaluated 48 h after OPN-siRNA2
transfection using immunofluorescence for Ki67. OPN
knockdown produced a significant reduction in Ki67
positive staining in both RJ348 (Fig. 4a) and RM11A
(Fig. 4b) cells compared to cells treated with the control
siRNA. Proliferation was also evaluated using immuno-
fluorescence for phosphorylated histone H3 and manual
cell counting using trypan blue exclusion. Both of these
experiments also showed a significant decrease in prolif-
eration in RJ348 cells treated with OPN-siRNA2 com-
pared to cells treated with the control siRNA (data not
shown). As an alternative approach, RJ348 proliferation
was assessed following incubation with 5 μg of an OPN
neutralizing antibody. As shown in Fig. 4c, treatment
with an OPN neutralizing antibody also significantly re-
duced RJ348 proliferation, albeit to a lesser extent.
Treating the RJ348 cells with 10 μg of OPN neutralizing
antibody resulted in a similar 20 % reduction in cell pro-
liferation (data not shown).
Apoptosis was evaluated 48 h after OPN-siRNA2
transfection using immunofluorescence for cleaved cas-
pase 3. OPN knockdown produced a significant increase
Table 1 OPN expression in tumors and tissue
Sample Spp1 (DNA Microarray)a Spp1 (qRT-PCR)b
WT 0.07 ± 0.04 1.3 ± 0.92
PMT 4.33 ± 1.13 675.2 ± 212.4
RST 0.59 ± 0.02 94.7 ± 48.7
aOPN expression relative to a murine reference DNA sample, WT (n = 8), PMT
(n = 12), RST (n = 8)
bOPN expression relative to housekeeping genes Hprt and Ywhaz,
WT (n = 4), PMT (n = 4), RST (n = 4)
Fig. 2 Immunohistochemistry for OPN protein in (a, b) two independent PMT tumors and (c, d) two independent RST tumors. The brown
staining indicates OPN protein which was expressed at only low levels in tumors cells of PMTs but at higher levels in the tumors cells or RSTs.
RST tumors varied in histology with some tumors being composed primarily of spindle-shaped cells (c) and other tumors composed primarily of
cells with squamous characteristics (d). Scale bars 100 μM
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in cleaved caspase 3 positive cells in both RJ348 (Fig. 4d)
and RM11A (Fig. 4e) cells compared to cells treated with
the control siRNA.
Migration and invasion were reduced following OPN
knockdown
Cell migration was initially assessed using a scratch
wound assay. RJ348 cells treated with OPN-siRNA2 had
significantly impaired migration compared to RJ348 cells
treated with the control siRNA at both the 24 and 48 h
time points (Fig. 5a). Cell migration was also assessed
using a transwell assay. Similar to the scratch wound
assay, OPN knockdown significantly reduced RJ348 cell
migration in the transwell assay (Fig. 5b-d). Scratch
wound assays are difficult to perform using the RM11A
cells as these cells have a disperse growth pattern and do
not tightly pack together. Therefore migration and inva-
sion was only evaluated in the RJ348 cells.
Proliferation and migration following OPN receptor
knockdown
The two main receptors reported for OPN are CD44
and integrin αVβ3, however, other integrin receptors are
also involved. Quantitative RT-PCR of Cd44, integrin αV
(Itgav), and integrin β3 (Itgb3) mRNA expression re-
vealed that only Cd44 and Itgav where highly expressed
in RJ348 cells (Table 3). Similar levels of expression were
observed in RM11A cells (Table 3).
To determine whether CD44 or integrin αV were me-
diating the effects of OPN in RJ348 cells, these proteins
were transiently knocked down using siRNA (RM11A
cells were not evaluated). Quantitative RT-PCR revealed
that Cd44 expression could be reduced to 12 % of the
control RNAi treated RJ348 cells (88 % knockdown)
while Itgav expression could be reduced to 32 % of con-
trol RNAi treated RJ348 cells (68 % knockdown).
Itgav knockdown significantly reduced proliferation
in RJ348 cells (Fig. 6a) while Cd44 knockdown in-
duced a small, non-significant reduction in RJ348 pro-
liferation (Fig. 6c). With respect to migration, Cd44
knockdown did not significantly reduce wound clos-
ure (Fig. 6d). Itgav knockdown appeared to negatively
impact cell adhesion in the scratch wound assay and
thus only a transwell assay was performed. Itgav
knockdown significantly reduce RJ348 transwell mi-
gration (Fig. 5b).
Fig. 3 Representative western blots showing OPN protein levels in (a) RM11A cell following no treatment, treatment with lipofectamine only,
treatment with a GC control siRNA or 3 different siRNAs targeting different regions on OPN mRNA. Representative western blots of OPN protein
level following no treatment, treatment with lipofectamine only, treatment with a GC control siRNA or treatment with OPN- siRNA2 in (b) RJ348
cells and (c) RM11A cells 24, 48 or 72 h after transfection
Table 2 OPN expression in mammary tumor cell lines
Sample Spp1 (qRT-PCR)a
RJ348 21.8 ± 5.7
RJ345 6.4 ± 1.9
RM11A 89.5 ± 13.2
aSpp1 expression relative to housekeeping genes Hprt and Ywhaz, RJ348
(n = 4), RJ345 (n = 4), RM11A (n = 4)
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Discussion
Our lab has generated a transgenic model of mammary
tumorigenesis. In this model, human IGF-IR is expressed
in mammary epithelial cells in a doxycycline inducible
manner and IGF-IR transgene expression induces mam-
mary tumor development [30]. Down-regulation of IGF-
IR transgene (through doxycycline withdrawal) in estab-
lished mammary tumors results in the regression of
most of the mammary tumors and tumor recurrence in
a subset of mice. Some of the recurrent mammary tu-
mors acquire a spindle-like morphology and no longer
express the IGF-IR transgene [33]. Gene expression ana-
lysis and clustering with human breast cancers revealed
that the IGF-IR induced mammary tumors (also known
as PMTs) express markers of luminal tumors but cluster
closely with human basal-like tumors with the recurrent
mammary tumors (also known as RSTs) express markers
of claudin-low tumors and cluster closely with human
Fig. 4 Quantification of (a, b) Ki67 immunofluorescence or (d, e) cleaved caspase 3 immunofluorescence in (a, d) RJ348 cells or (B,E) RM11A cells
after treatment with a GC control siRNA or OPN-siRNA2. The percentage of Ki67 positive or cleaved caspase 3 positive cells following OPN-siRNA2
treatment are presented relative to cells treated with the GC control siRNA. c phospho-histone H3 immunofluorescence in RJ348 cells following
administration of 5 μg of an OPN neutralizing antibody or 5 μg of a control antibody. The percentage of phospho-histone H3 positive cells
following OPN neutralizing antibody treatment is presented relative to the control antibody. A paired t-test was used to determine statistical
significance, *p˂0.05, n≥ 3
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claudin low breast cancers [31]. Claudin-low mammary
tumors are a subset of basal-like breast cancers that are
typically estrogen receptor, progesterone receptor and
HER2 negative, express low levels of claudins 2, 4 and 7
and have characteristics of progenitor cells [41–43].
Since the most differentially expressed gene between
normal mouse mammary tissue and IGF-IR induced
mammary tumors identified in our previous study was
Spp1, this gene was further examined in this current
manuscript in the transgenic model and cell lines de-
rived from the IGF-IR transgenic mice (MTB-IGFIR
transgenic mice).
Using cell lines derived from a PMT or two different
RSTs from the MTB-IGFIR transgenic mice we found
that the RST-derived cell lines (RJ348 and RM11A) had
higher expression of OPN than the PMT-derived cell
line (RJ345). This finding was somewhat surprising con-
sidering that PMTs in MTB-IGFIR transgenic mice had
higher OPN expression than RSTs and may suggest that
most of the OPN in the PMTs is produced by non-
tumor cells in the tumor microenvironment while the
tumor cells themselves are the main source of OPN in
the RSTs.
Immunohistochemical staining for OPN supported
this theory as positive OPN staining in tumor cells from
PMTs was typically low and sporadic, however, intense
OPN staining was observed in stromal cells surrounding
PMTs. In contrast, tumor cells in RSTs more frequently
stained positive for OPN protein than tumor cells of
PMTs. Studies in human breast cancer support this find-
ing in that OPN was negatively correlated with luminal
breast cancer subtypes [44] (no studies evaluating OPN
expression in human claudin-low tumors have been de-
scribed). Moreover, the human breast cancer cell line,
MCF-7, which possesses characteristics of luminal breast
cancer express lower levels of OPN than the human
claudin-low breast cancer cell line, MDA-MB-231 [45].
Therefore, luminal tumors may depend on OPN from
the microenvironment while claudin-low tumors may
produce OPN.
We focused on the murine claudin-low mammary
tumor cell lines since (1) the claudin-low murine mam-
mary tumor cells expressed high levels of OPN, (2)
claudin-low tumors are poorly understood, and (3)
claudin-low tumor do not respond well to conventional
therapies and thus alternative therapeutic strategies for
this type of tumor requires identification. Our findings
demonstrate that claudin-low mammary tumor cells rely
on OPN for proliferation, survival and migration as
knockdown of OPN using siRNA inhibited proliferation
and migration while increasing apoptosis. An OPN neu-
tralizing antibody was also capable of significantly inhi-
biting RJ348 proliferation albeit, less efficiently than
OPN knockdown (apoptosis was not evaluated). These
Fig. 5 Quantification of (a) RJ348 cell migration following treatment
with a GC control siRNA or OPN-siRNA2 as determined by a scratch
wound assay 24 or 48 h after scratch induction. Representative images
of RJ348 cells that migrated to the opposite side of a transwell assay
following treatment with (b) GC control siRNA or (c) OPN-siRNA2. The
bars represent mean ± SEM. A paired T-test was used to determine
statistical significance, *p˂0.05, n = 3. (d) Quantification of the number
of cells that migrated in the transwell assay after treatment with a GC
control siRNA or OPN-siRNA2. The bars represent mean ± SEM. A paired
t-test was used to determine statistical significance, *p˂0.05, n≥ 3
Table 3 Itgav, Itgb3 and Cd44 expression in mammary tumor
cell lines
Itgava Itgb3a Cd44a
RJ348 0.92 ± 0.14 0.012 ± 0.004 0.99 ± 0.12
RM11A 0.91 ± 0.11 0.013 ± 0.003 0.91 ± 0.11
aOPN expression relative to housekeeping genes, Hprt and Ywhaz
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findings are consistent with studies on MDA-MB-231
cells which showed that disruption of OPN function im-
paired proliferation [46, 47], survival [47–49] and migra-
tion [46, 48].
In an attempt to determine which receptors OPN was
interacting with, the two best-characterized OPN recep-
tors, CD44 and integrin αvβ3 (ITGAV and ITGB3) [50]
were examined. While RJ348 cells expressed considerable
amounts of Cd44 and Itgav mRNA, only very low levels of
Itgb3 were detected. To evaluate receptor function, Cd44
or Itgav mRNA was knocked down using siRNA. Only
knockdown of Itgav and not Cd44 significantly decreased
cell proliferation and migration suggesting that Itgav in as-
sociation with a β-integrin, other than β3, is mediating
OPN’s effects in RJ348 cells. OPN can also bind to αv con-
taining integrins αvβ1,αvβ5, and αvβ6 [8–10] and thus in
RJ348 cells, OPN is likely mediating at least some of its ef-
fects via one of these integrin receptors. RNA sequencing
has been performed on the RJ348 cells and Itgb1 and
Itgb5, but not Itgb6 are highly expressed in RJ348 cells and
thus presumably one of these two β-integrins are interact-
ing with Itgav to mediate OPN signaling. The only pub-
lished study that directly manipulated OPN receptors in
human breast cancer utilized a CD44 neutralizing anti-
body in MDA-MB-231 and they observed that antibody
mediated suppression of CD44 signaling inhibited migra-
tion [46]. Therefore, it remains unclear which receptors
mediate the physiologic effects of OPN in claudin-low
breast cancer.
Conclusions
Despite numerous studies implicating OPN in a variety of
cancers, therapeutic strategies targeting OPN function have
not materialized (OPN is being evaluated as a biomarker
for a number of human cancers including non-small cell
lung cancer, head and neck cancer, and pancreatic cancer
(www.clinicaltrials.gov)). Our work, combined with pub-
lished studies on MDA-MB-231 cells, argue that targeting
OPN in claudin-low breast cancers may prove to be an ef-
fective therapeutic approach however a more complete
Fig. 6 Quantification of (a, c) phospho-histone H3 immunofluorescence, (b) transwell migration and (d) scratch wound closure in RJ348 cells following treat-
ment with (a, b) siRNA targeting Itgav or (c, d) siRNA targeting Cd44. Both proliferation and migration are presented relative to a GC control siRNA. *p˂0.05, n≥ 3
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understanding of the OPN-receptor interactions as well as
development of potent/specific OPN inhibitors are required
to translate this strategy from the pre-clinical to clinical
setting.
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